Skip to content
111711171117

Drawing based on the label description. No photo yet.

“Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg are white to off white colored, oval shaped, biconvex film coated tablets, debossed with "1117" on one side and plain on other side”

1117 pill

Pill with imprint 1117 is white, oval, 16 mm and has been identified as Losartan Potassium and Hydrochlorothiazide 12.5 mg / 100 mg. It is used for high blood pressure and quitting smoking. It is supplied by Direct Rx.

Losartan Potassium and Hydrochlorothiazide 12.5 mg / 100 mg

Imprint
1117
Strength
Hydrochlorothiazide 12.5 mg / Losartan Potassium 100 mg
Used for
High blood pressure and quitting smoking
Color
White
Shape
Oval
Size
16 mm
Score
No score line
Form
Tablet
Manufacturer
Direct Rx
Drug class
ARB (blood pressure medicine)
NDC
61919-785, 13668-117, 61919-785-90

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Losartan and Hydrochlorothiazide pills and guides

What is Losartan and Hydrochlorothiazide used for?

Losartan and Hydrochlorothiazide is used for high blood pressure and quitting smoking.

Medicine type
ARB (blood pressure medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label

Hypertension

Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.

Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents.

Hypertensive Patients with Left Ventricular Hypertrophy

Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients.

From the FDA-approved label on DailyMed (published Aug 10, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows 1117 and the other side is plain.
  • It is white, oval, 16 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Hydrochlorothiazide, Losartan Potassium

Inactive: Cellulose, Microcrystalline, Talc, Silicon Dioxide, Magnesium Stearate, Titanium Dioxide, Anhydrous Lactose, Starch, Corn, Hypromellose 2910 (6 Mpa.s)

Other pills with imprint 1117

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Losartan and Hydrochlorothiazide pills